Quest Diagnostics Inc vs Wheaton Precious Metals Corp — how do they compare? Quest Diagnostics Inc trades at $230.94 (market cap $25.48B), while Wheaton Precious Metals Corp trades at $138.35 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 2.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Wheaton Precious Metals Corp for 66 Days on average.
| DGX | WPM | |
|---|---|---|
Market Cap | $25.48B | $61.17B |
Volume | 941,866 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $165.72 |
52-Week Low | $173.49 | $94.37 |
Typical Hold Time | 56 Days | 66 Days |
Enterprise Value | $31.23B | $63.05B |
Dividend Yield | 1.49% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% on the day, amid a bearish technical signal. The company reported record H1 2026 revenues and beat EPS estimates for three consecutive quarters, with strong profitability margins (gross margin 75.25%, net margin 64.66%). Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive given robust earnings momentum and analyst consensus (80% buy ratings, $164.80 price target). Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock offers exposure to precious metals with high margins but trades at premium valuations (P/E 29.94, P/S 19.36), requiring confidence in delivery of projected growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →